NCT01378143已完成2 期
A Phase II Clinical Study Using OCZ103-OS in Patients With Unresectable and Locally Recurrent or Metastatic Colorectal Cancer Undergoing Standard Chemotherapy (mFOLFOX6 or FOLFIRI) as Second-Line Treatment
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 53
- 试验地点
- 7
- 主要终点
- Overall survival (OS)
研究概览
简要总结
The purpose of this study is to investigate the safety and efficacy of the use of OCZ103-OS in combination with standard of care as a second line treatment in subjects with unresectable and locally recurrent or metastatic colorectal cancer.
详细描述
This is a single arm, open label study to investigate the safety and efficacy of the use of OCZ103-OS in combination with standard therapy (mFOLFOX6 or FOLFIRI) as a second line treatment in subjects with unresectable and locally recurrent or metastatic colorectal cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically or cytologically proven diagnosis of adenocarcinoma of the colon/rectum with evidence of (1) unresectable and, locally recurrent, or (2) metastatic disease.
- •Failure of first-line therapy(5-Fu-based therapy +/- bevacizumab) for metastatic colorectal cancer.
- •At least one (1) unidimensionally measurable lesion (on spiral CT scan).
- •18 years of age or older.
- •ECOG performance status 0, 1 or
- •Serum aspartate transaminase (AST), serum alanine transaminase (ALT), serum alkaline phosphatase (ALP) ≤ 2.5 x upper limit of normal (ULN), or AST,ALT, ALP ≤ 5 x ULN if liver function abnormalities are due to underlying malignancy
- •Total serum bilirubin ≤ 1.5 x ULN
- •Lipase and amylase within normal limits or abnormal limits but deemed not clinically significant.
- •Absolute neutrophil count (ANC) ≥ 1500/µL (1.5 x 10e9/L)
- •Platelets ≥ 100,000/µL (100 x 10e9/L)
- •Hemoglobin ≥ 90 g/L
- •Serum creatinine ≤ 1.5 x ULN or calculated creatinine clearance ≥ 60 ml/min. The Cockcroft-Gault formula to be used is as follows:
- •eCcr=(140-age)x Mass(in kilogram)x Constant/Serum Creatinine(in µmol/L)
- •Where Constant is 1.23 for men and 1.04 for women.
- •Normal or abnormal ECG. If ECG shows abnormalities, they must be deemed not clinically significant.
- •Signed and dated Informed Consent Form indicating that the subject (or legally acceptable representative) has been informed of all the pertinent aspects of the trial prior to enrollment.
- •Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other trial procedures.
- •Life expectancy, in the opinion of the investigator, > 3 months.
- •Exclusion criteria
- •Systolic Blood Pressure <100 mmHg (if deemed clinically significant by the treating physician).
- •Uncontrolled diabetes, severe renal impairment or pancreatitis.
- •Concomitant therapy with other investigational agents or participation in another clinical trial within 30 days prior to enrollment.
- •Any of the following conditions: Ongoing cardiac dysrhythmias of NCI CTCAE grade ≥ 2; atrial fibrillation of any grade; QTc interval > 450 msec for males or > 470 msec for females or uncontrolled intercurrent illness, e.g. unstable angina; severe coronary disease, ventricular arrhythmias, bradycardia < 50 bpm; a history of additional risk factors for torsades de pointes (e.g., heart failure, hypokalemia or family history of Long QT Syndrome).
- •Active uncontrolled bacterial infection.
- •Concurrent use of drugs that could prolong QT interval (NB: pentamidine is known to induce torsades de pointes) (see Appendix II: List of drugs that could prolong QT interval / we also suggest that you refer to the following link: http://www.azcert.org/medical-pros/drug-lists/bycategory.cfm).
- •Concurrent use of nephrotoxic drugs (depending on the medical health status of the patient and based on the judgment of the investigator), including but not limited to aminoglycosides, ampho B, foscarnet and cidofovir.
- •Concurrent use of drugs such as Rifampine and Lamivudine, since these that may be associated with pancreatitis.
- •Prior malignancy other than colorectal cancer (except for adequately treated carcinoma in situ of the cervix, non-melanoma skin cancer or localized prostate cancer with undetectable PSA level) unless the prior malignancy was diagnosed and definitively treated at least five (5) years previously with no subsequent evidence of recurrence.
- •Clinically significant non-malignant lung disease.
- •History of allergy or hypersensitivity to pentamidine.
- •Pregnancy or breastfeeding. All female patients with reproductive potential must have a negative pregnancy test (serum or urine) prior to first dose of study medication.
- •Severe acute or chronic medical or psychiatric condition, or laboratory abnormality that would impart, in the judgement of the investigator, excess risk associated with trial participation of study drug administration, or which in the judgement of the investigator, would make the subject inappropriate for entry into this trial.
- •Use of oral anticoagulants (LMWH is acceptable)
排除标准
- 未提供
研究组 & 干预措施
OCZ103-OS, mFOLFOX6 or FOLFIRI
Experimental
OCZ103-OS in combination with mFOLFOX6 or FOLFIRI as standard of care
干预措施: OCZ103-OS [pentamidine bis(2-hydroxyethanesulfonate)], mFOLFOX6 or FOLFIRI (Drug)
结局指标
主要结局
Overall survival (OS)
时间窗: 2 years
To assess the antitumor activity of OCZ103-OS in combination with standard of care in subjects with unresectable and locally recurrent or metastatic colorectal cancer in terms of overall survival
Progression free survival (PFS)
时间窗: 2 years
To assess the antitumor activity of OCZ103-OS in combination with standard of care in subjects with unresectable and locally recurrent or metastatic colorectal cancer in terms of progression free survival
Tumor size (CT scan)
时间窗: 2 years
To assess the antitumor activity of OCZ103-OS in combination with standard of care in subjects with unresectable and locally recurrent or metastatic colorectal cancer in terms of tumor growth during treatment
次要结局
- Peak plasma concentration (Cmax) of OCZ103-OS(2 months)
- Duration of response (DR)(2 years)
- Number of participants with Adverse Events (AE) as a Measure of Safety and Tolerability(2 years)
- Objective response (OR)(2 years)
研究者
研究点 (7)
Loading locations...
相似试验
已完成
2 期
An Exploratory Study of OCZ103-OS in Combination With Standard of Care in Stage IV Non-Small Cell Lung Cancer (NSCLC) PatientsNon-small Cell Lung CancerNCT01844791Oncozyme Pharma Inc.25
招募中
2 期
Prevention of Ototoxicity in NTM Patients Treated With IV AmikacinOtotoxicity, Drug-InducedNCT05730283Kevin Winthrop105
招募中
2 期
A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative ColitisColitis, UlcerativeNCT05076175Bristol-Myers Squibb120
进行中（未招募）
3 期
A Study of XZP-3287 in Combination With Letrozole/Anastrozole in Patients With Advanced Breast CancerAdvanced Breast CancerNCT05257395Xuanzhu Biopharmaceutical Co., Ltd.397
已完成
3 期
Safety and Efficacy of OMS302 in Subjects Undergoing Intraocular Lens Replacement With PhacoemulsificationIntraocular Lens ReplacementNCT01454063Omeros Corporation405